AngioDynamics (ANGO) Stock Price
AngioDynamics Price
AngioDynamics (ANGO) Stock | ISIN US03475V1017 | WKN A0B9A5. The current AngioDynamics stock price is 11.94 USD (2026). Revenue is 319.14 M USD. Net income is -12.19 M USD. The P/E ratio is -40.01. Market capitalization is 492.17 M USD. AngioDynamics operates in the Health sector.
Revenue has compounded at 7.2% per year over the past 19 years to 292.5 M USD. Earnings per share have grown at 9% per year over the last 13 years. AngioDynamics's net margin stands at -11.6%, broadly stable from -10.8% several years earlier.
AngioDynamics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of AngioDynamics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how AngioDynamics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing AngioDynamics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | AngioDynamics Price |
|---|
AngioDynamics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
AngioDynamics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|
| 338 | 303 | 292 | 319 | 334 | 353 | 369 | 388 |
| 6.96 | -10.36 | -3.63 | 9.25 | 4.7 | 5.69 | 4.53 | 5.15 |
| 51.48 | 50.83 | 53.77 | 49.22 | 47.01 | 44.48 | 42.55 | 40.46 |
| 174 | 154 | 157 | 157 | 157 | 157 | 157 | 157 |
| -52 | -184 | -33 | -12 | -4 | 8 | 12 | 14 |
| 100 | 253.85 | -82.07 | -63.64 | -66.67 | -300 | 50 | 16.67 |
| 39.5 | 40.18 | 40.85 | 40.85 | 40.85 | 40.85 | 40.85 | 40.85 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales AngioDynamics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue AngioDynamics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare AngioDynamics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares AngioDynamics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against AngioDynamics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
AngioDynamics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
AngioDynamics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
AngioDynamics business model & stock analysis
AngioDynamics SWOT Analysis
Strengths
1. Strong market presence: AngioDynamics Inc has established a strong presence in the medical device industry, particularly in the field of minimally invasive therapeutic and diagnostic technologies.
2. Diverse product portfolio: The company offers a wide range of innovative medical devices, including vascular access products, vascular interventions, angiographic products, and oncology systems, which cater to various healthcare needs.
3. Technological advancements: AngioDynamics Inc invests heavily in research and development to ensure continuous innovation and technological advancements in its products, enabling it to stay ahead of competitors.
4. Strong financial position: The company has demonstrated strong financial performance, with steady revenue growth and healthy profit margins, providing a solid foundation for future investments and expansion.
Weaknesses
1. Dependence on a limited customer base: AngioDynamics Inc heavily relies on a few key customers, which can pose a risk if any of them significantly reduce or terminate their business relationships with the company.
2. Regulatory challenges: The medical device industry is subject to strict regulations and compliance requirements, and any non-compliance can result in product delays or recalls, impacting the company's reputation and financial performance.
3. Limited global presence: While the company has a solid market presence in the United States, its international market penetration is relatively limited, which restricts its growth potential in global markets.
4. Intense competition: AngioDynamics Inc faces intense competition from both established medical device companies and emerging startups, which may result in price pressure and difficulty in maintaining market share.
Opportunities
1. Growing demand for minimally invasive procedures: There is an increasing trend towards minimally invasive surgeries and treatments, presenting an opportunity for AngioDynamics Inc to expand its market share in this rapidly growing segment.
2. Expansion into emerging markets: The company can capitalize on the growing healthcare infrastructure in emerging markets by expanding its global presence and partnering with local distributors or healthcare providers.
3. Strategic collaborations and acquisitions: AngioDynamics Inc can explore strategic collaborations or acquisitions to enhance its product portfolio, gain access to new technologies, and expand its customer base.
4. Focus on oncology market: The rising prevalence of cancer and increasing adoption of minimally invasive treatments in oncology create opportunities for the company to develop specialized products and solutions catering to this market segment.
Threats
1. Economic downturns: Any economic downturn or financial crisis can impact healthcare spending, leading to a decrease in demand for medical devices and potentially affecting AngioDynamics Inc's sales and revenue.
2. Stringent regulatory environment: The medical device industry is subject to evolving and complex regulations, and compliance failures can lead to penalties, product recalls, or a halt in manufacturing, which may affect the company's operations and financial performance.
3. Price pressure from competitors: Intense competition within the industry can result in price wars and reduced profit margins, especially if competitors offer similar products at lower prices, posing a threat to AngioDynamics Inc's market position.
4. Technological obsolescence: Rapid advancements in technology and medical innovations could render existing products obsolete, necessitating continuous investments in research and development to stay ahead of market trends.
AngioDynamics Segments
AngioDynamics Revenue by Segment (1/4)
Max
Details
AngioDynamics Revenue by Segment (2/4)
Max
Details
AngioDynamics Revenue by Segment (3/4)
3 Years
5 Years
10 Years
25 Years
Max
Details
AngioDynamics Revenue by Segment (4/4)
Max
Details
AngioDynamics Revenue by Region
3 Years
5 Years
10 Years
Max
Details
AngioDynamics Eulerpool Fair Value
AngioDynamics historical P/E ratio, EBIT multiple, and P/S ratio
AngioDynamics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
AngioDynamics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
AngioDynamics Earnings Estimates
AngioDynamics Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 4/2/2026 | -0.11USD | 78.3 MUSD | 2026 Q3 |
| 1/6/2026 | -0.1USD | 77.83 MUSD | 2026 Q2 |
| 3/28/2024 | -0.08USD | 80.97 MUSD | 2024 Q3 |
| 1/3/2024 | 0.03USD | 92.98 MUSD | 2024 Q2 |
| 10/4/2023 | -0.13USD | 79.35 MUSD | 2024 Q1 |
| 10/6/2022 | -0.02USD | 84.67 MUSD | 2023 Q1 |
EESG©
Eulerpool ESG Scorecard© for the AngioDynamics stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
AngioDynamics shareholder structure
| % | Name |
|---|---|
8.23734% | |
7.19167% | |
6.08905% | |
6.0389% | |
5.20594% | |
4.72803% | |
3.70649% | |
3.29134% | |
2.84469% | |
2.73572% |
AngioDynamics Executives and Management Board
Mr. James Clemmer
(61)President, Chief Executive Officer, Director · since 2016
Mr. Stephen Trowbridge
(50)Chief Financial Officer, Executive Vice President
Ms. Laura Piccinini
(55)Senior Vice President, General Manager - Endovascular Therapies and International
Mr. Lawrence Weiss
(56)Senior Vice President, Chief Legal Officer and Corporate Secretary
Mr. Warren Nighan
(55)Senior Vice President - Global Supply Chain, Quality and Regulatory Affairs
AngioDynamics Supply Chain
Frequently asked questions about AngioDynamics
AngioDynamics Inc operates as a medical device company, specializing in the design, development, manufacturing, and marketing of medical, surgical, and diagnostic devices used in minimally invasive procedures. The company's business model focuses on providing innovative solutions to healthcare professionals for the treatment of vascular diseases and conditions. AngioDynamics offers a wide range of products, including ablation systems, thrombus management devices, venous access products, and peripheral vascular devices. By delivering high-quality and reliable medical devices, AngioDynamics aims to improve patient outcomes and provide value to healthcare providers.
AngioDynamics stock
AngioDynamics Peer Group
AngioDynamics Ticker
AngioDynamics FIGI
All fundamentals and in-depth analysis of AngioDynamics
Our stock analysis for AngioDynamics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AngioDynamics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.